Shield Therapeutics PLC Directorate Change (2651Q)
05 June 2018 - 4:01PM
UK Regulatory
TIDMSTX
RNS Number : 2651Q
Shield Therapeutics PLC
05 June 2018
Shield Therapeutics plc
("Shield" or the "Company")
Directorate Change
London, UK, 5 June 2018. Shield Therapeutics plc (LSE:STX),
announces that Dr Andrew Heath has notified the Company of his
intention to step down as Chairman, and from the Board, by not
standing for re-election at the upcoming AGM so that he may focus
on other business interests. Dr Heath has worked closely with
Shield Therapeutics since 2015, initially as a senior advisor,
before joining the Board as Non-Executive Chairman in early 2016.
During this time, he has played a key role in helping the Company
to successfully achieve an initial public offering on the London
Stock Exchange and has been integral to the subsequent development
of the Company.
A process to appoint a successor is underway.
Carl Sterritt, Chief Executive Officer of Shield Therapeutics
commented "On behalf of the Board, I would like to thank Andrew for
his considerable contribution to the development and transformation
of Shield Therapeutics from a private, development stage company to
a commercially-focused and publicly listed entity. His experienced
counsel during this period of significant transition for the
Company has been greatly appreciated and I offer him our best
wishes."
Dr Andrew Heath, Non-Executive Chairman, said "I have thoroughly
enjoyed my time at Shield Therapeutics and am proud to have been at
the head of the team that has built the Company into a commercial
stage publicly listed specialty pharmaceutical company. Through its
people and assets Shield has the foundations in place for a
successful future and I wish Carl and the team the very best of
luck with their ongoing endeavours."
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Karl Keegan, Chief Financial Officer
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a commercial stage pharmaceutical
company, delivering innovative specialty pharmaceuticals to address
patients' unmet medical needs. Our clear purpose is to help our
patients become people again, by enabling them to enjoy the things
that make the difference in their everyday lives. The Group has a
marketed product, Feraccru(R), for the treatment of all adults with
iron deficiency with or without anaemia which has exclusive IP
rights until the mid-2030's. For more information please visit
www.shieldtherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAZMGGVGDFGRZZ
(END) Dow Jones Newswires
June 05, 2018 02:01 ET (06:01 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024